Open Access

The protective effect of hydromorphone to ischemia in rat glial cells

  • Young Sung Kim1,
  • Woon Young Kim2,
  • Yeon-hwa Kim3,
  • Ji Won Yoo4 and
  • Too Jae Min2Email author
SpringerPlus20165:610

https://doi.org/10.1186/s40064-016-2281-7

Received: 4 February 2016

Accepted: 5 May 2016

Published: 12 May 2016

Abstract

Background

Ischemic insults during operation can cause ischemic-reperfusion injuries in brain as well as memory impairments. Total intravenous anesthesia (TIVA) is the preferred anesthetic method in brain surgery, as it utilizes motor evoked potential monitoring. And the use of opioids is common in TIVA. However there are few studies about ischemic protective effect of opioids to glial cells.

Methods

We used mixed cultures of rat glial cells, which were harvested from the brain of 1-day old rat. We divided the experimental groups according to their hydromorphone conditioning period: (a) pre-culture, (b) per-culture, or (c) pre- and per-culture. We measured the levels of the reactive oxygen species (ROS) induced by tert-butyl hydroperoxide (TBH) using flow cytometry. The ROS levels in the glial cells were also measured after the administration of 100 nM hydromorphone and selective opioid receptor antagonists.

Results

The ROS levels were reduced in the hydromorphone-treated group, as compared to the control group (only TBH treated). There were no differences between pre-conditioned and per-conditioned groups. However, the ROS levels were more reduced in pre- and per-conditioned group compared to pre-conditioned or per-conditioned only groups. Furthermore, selective antagonists for the delta, kappa, or mu opioid receptor partially negated the hydromorphone effect.

Conclusion

This study demonstrated that hydromorphone can have additional protective effects on oxidative stress when pre- and per-conditioning is combined. Furthermore we proved that μ, δ, κ opioid receptors participate in protective mechanism of hydromorphone to glial cells.

Keywords

Hydromorphone Neuroglia Reactive oxygen species

Background

In recent times, glial cells are considered to represent a specialized functional unit with neurons, in addition to providing neuronal support. Glial dysfunction can cause cognitive disorders as well as short-term memory loss (Vicente et al. 2009; Maragakis and Rothstein 2006). Ischemic shock during surgery can induce ischemic-reperfusion injuries in the brain and memory impairments (Bilotta et al. 2013). Many studies have established that opioids are protective against ischemia and reperfusion in different cell types (Gross et al. 2010; Goldsmith et al. 2013). However, there are few studies that evaluate the protective effects of opioids in glial cells under ischemic conditions. Although opioids induce preconditioning effects in glial cells in the brain (Gwak et al. 2010), it is unknown whether opioids also have perconditioning effects.

Currently, total intravenous anesthesia (TIVA) is the preferred technique of anesthesia during neurosurgery due to its use of motor evoked potential (MEP) monitoring (Scheufler and Zentner 2002). The perioperative use of opioids is common in such settings. Therefore, it is meaningful to investigate whether opioids possess pre- and per-conditioning effects on glial cells. In this study, we evaluated whether hydromorphone had pre- and per-conditioning effect on glial cells. Furthermore we sought to determine whether hydromorphone had additive effects when pre- and per-conditioning were combined.

Methods

Chemicals

Hydromorphone was purchased from Hanapharm Co. (Seoul, Korea). Tert-butyl hydroperoxide (TBH, t-BOOH) and 2′,7′-dichloroflurorescin diacetate (DCF-DA) were purchased from Sigma Chemical Co. (St Louis, MO, USA). The anti-glial fibrillary acidic protein (GFAP) primary antibody and Alexa Fluor 488 goat anti-mouse antibody were purchased from Millipore Co. (Billerica, MA, USA) and Invitrogen Co. (Carlsbad, CA, USA), respectively. XTT was purchased from WELLGNE Inco. (Dalseo-gu, Daegu, Republic of Korea). The mounting solution was purchased from Vector Laboratories (Burlingame, CA, USA).

Mixed primary rat glial cell culture

Rat glial cells were harvested and purified by the methods of previous study (de Vellis and Cole 2012). Pregnant Sprageue Dawley rat were purchased from Orientbio Co. (Seongnam-si, Gyeonggi-do, Republic of Korea). The rat cerebral cortices were purified from the brains of 1-day old rat pups, and then cultured in Dulbecco’s modified Eagle’s medium (DMEM) media supplemented with 10 % fetal bovine serum, 1 % antibiotics at 37 °C, and 5 % CO2 for 2 weeks. After 2 weeks, neurons, meningeal cells and fibroblasts were diminished, meanwhile microglial cells and astrocytes were replaced. We confirmed by immunostaining with anti-GFAP primary antibody via confocal microscope (Nikon A1si, Nikon, Japan). All procedures were reviewed and approved by the Committee on the Ethics of Animal Experiments of the Korea University Medical School. (IRB KUIACUC-2015-253)

Cell viability

Cell viability was measured by XTT (2,3-bis-2-methoxy-4-nitro-5-sulfophenyl-2H- tetrazolium-5-carboxanilide inner salt, WelCount Cell Viability Assay kit). The mixed glial cells were cultured in a 96-well plate. The control, TBH (100 µM) and/or hydromorphone (100 nM) treated glial cells were placed in a new DMEM media, containing a 5 % XTT reaction mixture (50:1 = XTT solution: PMS solution) and incubated in a CO2 incubator, at a temperature of 37 °C for a period of 2 h. The XTT assay generated formazan crystals, which were measured spectro-photometrically with an ELISA reader (690 nm).

Experimental protocol

The production of ROS in mixed glial cells was induced by TBH, which is organic peroxide (Peters et al. 2001), and then ROS was measured by flow cytometry using DCF-DA. The glial cells were proliferated to 5 × 104 cells in 6-well plates, and then transferred to a serum-free media, which was prepared by overnight serum starvation. The cells were divided into 4 experimental groups : (1) pre-culture period (administration of 100 nM hydromorphone for 1 h, and then the media was changed to a serum-free media prior to 100 µM of TBH administration.); (2) per-culture period (100 nM of hydromorphone and 100 µM of TBH were co-treated.); (3) pre- and per-culture (100 nM of hydromorphone was pretreated for 1 h, and then the media was changed to a serum-free media. In addition, 100 µM of TBH and 100 nM of hydromorphone co-administrated for 30 min.); and (4) opioid receptor antagonist groups (pretreatment of 100 nM hydromorphone for 1 h, along with a selective delta- (δ-), kappa- (κ-), or mu-(μ-) opioid receptor antagonist, then cells were co-treated with TBH, opioid receptor antagonist, and 100 nM of hydromorphone) (Fig. 1). The dosage of opioid receptor antagonists were determined by previous study (Min et al. 2011). Also, Pilot study for determining the dosage of hydromorphone was performed. Three different doses (10, 100, 1000 nM) of hydromorphone were administrated. Each dosage of hydromorphone was treated for 1 h before 100 µM of TBH treatment (Fig. 2).
Fig. 1

Experimental design. TBH: tert-butyl hydroperoxide, DCF-DA: 2′,7′-dichloroflurorescin diacetate, OR antagonist : naltrindole (a selective delta opioid receptor antagonist) or nor-binaltorphimine (a selective kappa opioid receptor antagonist) or naloxone

Fig. 2

This graph shows effective dosage of hydromorphone for reducing ROS. The amount of ROS was expressed as Mean Fluorescence index. *<0.05 versus TBH group. <0.05 versus 10 nM hydromorphone group

The measurement of the intracellular reactive oxygen species (ROS) production

Flow cytometry

The control-, TBH- (100 µM) and/or hydromorphone- (100 nM) treated glial cells were incubated in a CO2 incubator with DCF-DA (10 µg/ml) at 37 °C for 20 min. The DCF-DA-treated glial cells were washed with phosphate-buffered saline (PBS) and detached from the plate using trypsin–EDTA (0.25 %). The detached cells were diluted with PBS (300 µl) for analysis by flow cytometry. At least three different sets of experiments were performed using cells from different isolations.

TUNEL assay for apoptosis detection in glial cells

Apoptosis is characterized by DNA fragmentation, which can be detected by selective staining. A terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) apopto-sis staining kit (Roche Molecular Biochemicals, Mannheim, Ger-many) was used to detect programmed cell death. The glial cells were treated with hydromorphone (100 nM) for the pre-/per-period with TBH (100 µM) for 30 min), followed by fixation and TUNEL staining. The fixed cells were washed 3 times with PBS containing 0.1 %-Tween 20. The en-zyme and label solutions in the TUNEL stain kit were thoroughly mixed and reacted at 37 °C for 1 h. After the re-action, the cells were washed 3 times with PBS containing 0.1 %-Tween 20 and then examined using a confocal micro-scope. Three slides were examined for each group, and then particles were counted from 10 different parts of each slide.

Statistical analysis

We used SPSS (Windows version 10.0, Chicago, IL, USA) for statistical analysis. All results are expressed as a mean ± standard deviation (SD) and are representative of three different experiments. The flow cytometry results were evaluated by one-way Anova. P values greater than 0.05 were considered significant.

Results

Cell viability

The cell survival rate after TBH was 84 %. This was calculated as a mean value.

Hydromorphone dosage

The cells that were treated with 100 or 1000 nM of hydromorphone had significantly lower levels of ROS compared to those in the TBH-treated group (Fig. 2). There were no differences between ROS levels in the 100 and 1000 nM groups.

The effects of TBH and/or hydromorphone on reactive oxygen species (ROS) production

The ROS production was lower in the hydromorphone-treated group compared to the control group treated with TBH only. Moreover, the ROS production was significantly lower in the pre- and per-conditioned groups compared to the pre-conditioned or the per-conditioned alone groups (Fig. 3).
Fig. 3

Detection of intracellular ROS (reactive oxygen species) product. This graph shows the protective effect of hydromorphone on TBH induced toxicity in primary rat glial cell cultures. The ROS level was measured with using FACS (DCF-DA) in the 100 nM hydromorphone (1) pre conditioned (2) per-conditioned (3) pre- and per- conditioned primary rat glial cells. The amount of ROS was expressed as Mean Fluorescence index. *<0.05 versus TBH group. <0.05 versus preconditioning group. <0.05 versus perconditioning group

The effect of opioid antagonists on reactive oxygen species (ROS) production

The production of ROS was reduced in the hydromorphone-treated group. However, each of the selective δ-, κ-, and μ-opioid receptor antagonists partially negated the hydromorphone effects on ROS production (Fig. 4).
Fig. 4

Effects of opioid receptor (OR) antagonists on reactive oxygen species (ROS) products. This graph shows that selective OR antagonists reverse the attenuation of the ROS induced by hydromorphone (pre and per-condition). The ROS level was measured with using FACS (DCF-DA) in the cells treated only TBH (control group), and the cells treated with TBH, hydromorphone and/or one of selective delta, kappa, and mu opioid receptor antagonists, naltrindole, nor-binaltorphimine, and naloxone, respectively. The amount of ROS was expressed as Mean Fluorescence index.*<0.05 versus control group. +<0.05 versus hydromorphone group

TUNEL assay in glial cells

The apoptotic cells appeared as light red dots under a fluorescent microscope after performing the TUNEL as-say. A comparison between the TBH group and the pre- and per-conditioned group revealed that there were significantly less apoptotic cells in the pre- and per-conditioned group. Furthermore, the number of apoptotic cells in the opioid receptor blocker group was significantly increased (Figs. 5, 6).
Fig. 5

Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay of rat glial cells. a Fluorescence micrographs of cells were stained with rhodamine and DAPI. Red particles represent DNA fragments. This graphs show the Control, TBH, and Hydromorphone groups. b Fluorescence micrographs of cells were stained with rhodamine and DAPI. Red particles represent DNA fragments. This graphs show the opioid antagonist groups. <0.05 versus hydromorphone group

Fig. 6

Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay of rat glial cells. a This graph shows quantitation of apoptotic cells from TUNEL assay by number of red particles. *<0.05 versus TBH group. <0.05 versus hydromorphone group

Discussion

Currently, TIVA is the preferred method for general anesthesia during cerebral surgery because TIVA barely affects MEP monitoring (Zhang et al. 2011, 2004). Opioid use for intra-operative analgesia is common in TIVA. In this study, we demonstrated the pre-conditioning and per-conditioning effects of hydromorphone, providing evidence for the peri-operative effectiveness of hydromorphone.

Recent studies have shown that opioids, including morphine, have protective preconditioning effects in several ischemia/reperfusion models (Zhang et al. 2011, 2004). Morphine has anti-neuroinflammatory properties and can prevent memory deficits due to its preconditioning effect, which is dependent on opioid receptors (Rostami et al. 2012). However, the role of opioids in glial cells is unclear. Although glial cells play an important role in the antioxidant defense system in the brain (Iwata-Ichikawa et al. 1999), they are considered to be functional units rather than the barriers of neurons. Glial cell dysfunction can cause cognitive impairments and short-term memory loss (Vicente et al. 2009; Maragakis and Rothstein 2006). In addition, neuroinflammation is highly associated with ischemic stroke-induced cerebral damage and the progression of neurodegenerative diseases (Mucke and Eddleston 1993; Kreutzberg 1996; Brown and Bal-Price 2003). Glial cells are important because they are responsible for the brain’s neurophysiology and hence, represent potential therapeutic targets.

Excessive oxidative stress produces excessive ROS. These ROS play important roles to CNS damage during ischemic conditions (Kontos 1989) and are associated with a variety of diseases (Hu et al. 2015). Although a certain amount of ROS is essential for cellular survival, cell death can occur when ROS-induced oxidative stress exceeds a cell’s antioxidant capabilities (Hu et al. 2015; Yan 2014). Excessive ROS production can cause DNA damage, modify protein and lipid functions, and activate signal pathways (Yan 2014). However, a moderate level of oxidative stress, referred to as positive oxidative stress, can be induced and modulated to produce an adaptive cellular response that is beneficial for cellular survival. Both preconditioning and per-conditioning effects can potentially be the result of positive oxidative stress (Yan 2014; Milisav et al. 2012). Brief episodes of ischemia and reperfusion, and a number of pharmacological agents, can induce these phenomena (Das and Das 2008). TBH is commonly used to induce oxidative stress in vitro and in vivo (Rush et al. 1985). In this study, we used TBH to induce oxidative stress-related injury to rodent-derived glial cells (Holownia et al. 2009).

Several studies have demonstrated that morphine is involved in immune system functions (Hutchinson et al. 2007; Madera-Salcedo et al. 2011). Morphine exhibits both peripheral anti-inflammatory and inflammatory roles (Askari et al. 2008; Pourpak et al. 2004). Although opioids can induce glial activation and neuroinflammatory reactions (Watkins et al. 2009), morphine-induced preconditioning has been found to be anti-neuroinflammatory (Rostami et al. 2012). In these studies, we used hydromorphone, an opioid receptor agonist and morphine derivative (Ricket et al. 2015), to prevent TBH-induced ROS production. Hydromorphone, one of the first line opioids as per the European guideline (Oosten et al. 2015), is widely used for acute and chronic pain management in both adults and children (Oosten et al. 2015; Mherekumombe and Collins 2015). Compared to morphine, hydromorphone has certain clinical advantages, such as reduced nausea and vomiting (Wirz et al. 2008), and lower histamine release (Guedes et al. 2007). To demonstrate its protective effect, we used hydromorphone to induce oxidative stress-related injury. Because there are few in vitro studies using hydromorphone, we choose an equi-analgesic dosage of hydromorphone as compared to morphine, based on previous studies (Min et al. 2011; Lee et al. 2012). Pilot studies determined the maximum effective dose of hydromorphone for a pre-/per-conditioning effect, which was 100 nM (Fig. 1).

In this study, hydromorphone was protective against TBH-induced oxidative stress-related injury. Interestingly, the combined administration of hydromorphone (pre-conditioning followed by co-administration) had a superior effect compared to pre-conditioning and co-administration treatments alone. Opioids can not only suppress responses to various noxious stimuli (e.g., short cyclic episodes of ischemia or ROS), but also have similar pre-conditioning effects (Rostami et al. 2012; Das and Das 2008). This cumulative effect of hydromorphone may be important for clinical settings, such as the perioperative use of hydromorphone in neurosurgery.

The endogenous opioids and their receptors (μ-, δ-, κ-) are widely distributed in the glials like astrocytes (Pearce et al. 1985), oligodendrocytes (Knapp et al. 1998) and microglial cells (Calvo et al. 2000; Turchan-Cholewo et al. 2008). They exert their physiological effects, including nociception, analgesia, and brain development. Recently, Jeong et al. (2012) reported that remifentanil which is selective agonist for δ-opioid receptor, has neuroprotective effect to both neurons and glial cells, improves neurological scores, and reduces infarct volumes via the attenuation of mitogen-activated protein kinases (MAPK). MAPK involves ROS production and the release of pro-inflammatory cytokines (Son et al. 2011). But the protective effects of μ- and κ-opioid receptors to cerebral ischemia are still controversial. Some of studies have elucidated the protective function of κ-opioid receptors to reperfusion injury in ischemic cerebral animal models (Zhang et al. 2003; Goyagi et al. 2003). These effects are mediated through reducing NO production. Goyagi et al. (2003) showed that activation of κ-opioid receptors attenuates the evokation of NMDA by inhibiting excitatory postsynaptic potentials, and NMDA is involved in the NO production of brain. NMDA receptors are abundant in glial cells and neurons, and have important roles to maintain the homeostasis of brain (Verkhrataky and Kirchhoff 2007). These evoked N-Methyl-d-aspartic acid (NMDA) also induces ROS products (Shelat et al. 2008). Our results demonstrate that each opioid receptor subtype, the μ-, δ-, and κ-opioid receptor, reduces ROS production and is involved in the protective effects of hydromorphone in mixed glial cells. After administration of selective μ-, δ-, and κ-opioid receptor antagonists, ROS production was similar to that of the TBH-treated group, suggesting that the μ-, δ-, and κ-opioid receptors all contribute to hydromorphone’s protective effects. Our data also suggest that hydromorphone has pre and per conditioning effects as well. Considering the present results, MAPK pathways and NMDA signaling pathways might be involved in the protective effect of hydromorphone on TBH-induced glial cells. Further studies are required to evaluate the mechanism underlying opioid receptors involvement by using knockout models.

In conclusion, this study provides evidence that hydromorphone has both, pre-conditioning and per-conditioning effects on the TBH-induced injuries. Furthermore, pre- and per-conditioning effects of hydromorphone is additive. We also demonstrated that the μ-, δ-, and κ-opioid receptors all contributes to the mechanism of hydromorphone and its protective effect on glial cells. Hence, our findings support the therapeutic potential for hydromorphone in the prevention of ischemic cerebral injury during the perioperative period.

Abbreviations

TBH: 

tert-butyl hydroperoxide

ROS: 

reactive oxygen species

TIVA: 

total intravenous anesthesia

MEP: 

motor evoked potential

Declarations

Authors’ contributions

All authors contributed in the overall process of the experiment. Supported by Korea University Medical School. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Department of Anesthesiology, Korea University College of Medicine
(2)
Department of Anesthesiology and Pain Medicine, Korea University Ansan Hospital
(3)
Institute of Medical Science, Korea University Ansan Hospital, Korea University College of Medicine
(4)
Department of Internal Medicine and Institute of Gerontology, University of Nevada, School of Medicine

References

  1. Askari N, Mahboudi F, Haeri-Rohani A, Kazemi B, Sarrami R, Edalat R, Ahmadiani A (2008) Effects of single administration of morphine on G-protein mRNA level in the presence and absence of inflammation in the rat spinal cord. Scand J Immunol 67(1):47–52. doi:https://doi.org/10.1111/j.1365-3083.2007.02043.x View ArticleGoogle Scholar
  2. Bilotta F, Gelb AW, Stazi E, Titi L, Paoloni FP, Rosa G (2013) Pharmacological perioperative brain neuroprotection: a qualitative review of randomized clinical trials. Br J Anaesth 110(Suppl 1):i113–120. doi:https://doi.org/10.1093/bja/aet059 View ArticleGoogle Scholar
  3. Brown GC, Bal-Price A (2003) Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 27(3):325–355. doi:https://doi.org/10.1385/MN%3A27%3A3%3A325 View ArticleGoogle Scholar
  4. Calvo CF, Cesselin F, Gelman M, Glowinski J (2000) Identification of an opioid peptide secreted by rat embryonic mixed brain cells as a promoter of macrophage migration. Eur J Neurosci 12:2676–2684View ArticleGoogle Scholar
  5. Das M, Das DK (2008) Molecular mechanism of preconditioning. IUBMB Life 60(4):199–203. doi:https://doi.org/10.1002/iub.31 View ArticleGoogle Scholar
  6. de Vellis J, Cole R (2012) Preparation of mixed glial cultures from postnatal rat brain. Methods Mol Biol 814:49–59. doi:https://doi.org/10.1007/978-1-61779-452-0_4 View ArticleGoogle Scholar
  7. Goldsmith JR, Perez-Chanona E, Yadav PN, Whistler J, Roth B, Jobin C (2013) Intestinal epithelial cell-derived mu-opioid signaling protects against ischemia reperfusion injury through PI3K signaling. Am J Pathol 182(3):776–785. doi:https://doi.org/10.1016/j.ajpath.2012.11.021 View ArticleGoogle Scholar
  8. Goyagi T, Toung TJ, Kirsch JR, Traystman RJ, Koehler RC, Hurn PD, Bhardwaj A (2003) Neuroprotective kappa-opioid receptor agonist BRL 52537 attenuates ischemia-evoked nitric oxide production in vivo in rats. Stroke 34(6):1533–1538. doi:https://doi.org/10.1161/01.STR.0000072512.30658.E7 View ArticleGoogle Scholar
  9. Gross GJ, Baker JE, Hsu A, Wu HE, Falck JR, Nithipatikom K (2010) Evidence for a role of opioids in epoxyeicosatrienoic acid-induced cardioprotection in rat hearts. Am J Physiol Heart Circ Physiol 298(6):H2201–2207. doi:https://doi.org/10.1152/ajpheart.00815.2009 View ArticleGoogle Scholar
  10. Guedes AG, Papich MG, Rude EP, Rider MA (2007) Comparison of plasma histamine levels after intravenous administration of hydromorphone and morphine in dogs. J Vet Pharmacol Ther 30(6):516–522. doi:https://doi.org/10.1111/j.1365-2885.2007.00911.x View ArticleGoogle Scholar
  11. Gwak MS, Li L, Zuo Z (2010) Morphine preconditioning reduces lipopolysaccharide and interferon-gamma-induced mouse microglial cell injury via delta 1 opioid receptor activation. Neuroscience 167(2):256–260. doi:https://doi.org/10.1016/j.neuroscience.2010.02.017 View ArticleGoogle Scholar
  12. Holownia A, Mroz RM, Wielgat P, Skiepko A, Sitko E, Jakubow P, Kolodziejczyk A, Braszko JJ (2009) Propofol protects rat astroglial cells against tert-butyl hydroperoxide-induced cytotoxicity; the effect on histone and cAMP-response-element-binding protein (CREB) signalling. J Physiol Pharmacol 60(4):63–69Google Scholar
  13. Hu Y, Wang S, Wang A, Lin L, Chen M, Wang Y (2015) Antioxidant and hepatoprotective effect of Penthorum chinense Pursh extract against t-BHP-induced liver damage in L02 cells. Molecules 20(4):6443–6453. doi:https://doi.org/10.3390/molecules20046443 View ArticleGoogle Scholar
  14. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR (2007) Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci World J 7:98–111. doi:https://doi.org/10.1100/tsw.2007.230 View ArticleGoogle Scholar
  15. Iwata-Ichikawa E, Kondo Y, Miyazaki I, Asanuma M, Ogawa N (1999) Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis. J Neurochem 72(6):2334–2344View ArticleGoogle Scholar
  16. Jeong S, Kim SJ, Jeong C, Lee S, Jeong H, Lee J, Yoo KY (2012) Neuroprotective effects of remifentanil against transient focal cerebral ischemia in rats. J Neurosurg Anesthesiol 24(1):51–57. doi:https://doi.org/10.1097/ANA.0b013e3182368d70 View ArticleGoogle Scholar
  17. Knapp PE, Maderspach K, Hauser KF (1998) Endogenous opioid system in developing normal and jimpy oligodendrocytes: mu and kappa opioid receptors mediate differential mitogenic and growth responses. Glia 22(2):189–201View ArticleGoogle Scholar
  18. Kontos HA (1989) Oxygen radicals in CNS damage. Chem Biol Interact 72(3):229–255View ArticleGoogle Scholar
  19. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19(8):312–318View ArticleGoogle Scholar
  20. Lee YS, Park YC, Kim JH, Kim WY, Yoon SZ, Moon MG, Min TJ (2012) Intrathecal hydromorphone added to hyperbaric bupivacaine for postoperative pain relief after knee arthroscopic surgery: a prospective, randomised, controlled trial. Eur J Anaesthesiol 29(1):17–21. doi:https://doi.org/10.1097/EJA.0b013e3283476055 View ArticleGoogle Scholar
  21. Madera-Salcedo IK, Cruz SL, Gonzalez-Espinosa C (2011) Morphine decreases early peritoneal innate immunity responses in Swiss–Webster and C57BL6/J mice through the inhibition of mast cell TNF-alpha release. J Neuroimmunol 232(1–2):101–107. doi:https://doi.org/10.1016/j.jneuroim.2010.10.017 View ArticleGoogle Scholar
  22. Maragakis NJ, Rothstein JD (2006) Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol 2(12):679–689. doi:https://doi.org/10.1038/ncpneuro0355 View ArticleGoogle Scholar
  23. Mherekumombe MF, Collins JJ (2015) Patient-controlled analgesia for children at home. J Pain Symptom Manag 49(5):923–927. doi:https://doi.org/10.1016/j.jpainsymman.2014.10.007 View ArticleGoogle Scholar
  24. Milisav I, Poljsak B, Suput D (2012) Adaptive response, evidence of cross-resistance and its potential clinical use. Int J Mol Sci 13(9):10771–10806. doi:https://doi.org/10.3390/ijms130910771 View ArticleGoogle Scholar
  25. Min TJ, Kim JI, Kim JH, Noh KH, Kim TW, Kim WY, Lee YS, Park YC (2011) Morphine postconditioning attenuates ICAM-1 expression on endothelial cells. J Korean Med Sci 26(2):290–296. doi:https://doi.org/10.3346/jkms.2011.26.2.290 View ArticleGoogle Scholar
  26. Mucke L, Eddleston M (1993) Astrocytes in infectious and immune-mediated diseases of the central nervous system. FASEB J 7(13):1226–1232Google Scholar
  27. Oosten AW, Oldenmenger WH, Mathijssen RH, van der Rijt CC (2015) A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J Pain 16(10):935–946. doi:https://doi.org/10.1016/j.jpain.2015.05.006 View ArticleGoogle Scholar
  28. Pearce B, Cambray-Deakin M, Murphy S (1985) Astrocyte opioid receptors: activation modifies the noradrenaline-evoked increase in [2-14C] deoxyglucose incorporation into glycogen. Neurosci Lett 55:157–160View ArticleGoogle Scholar
  29. Peters CE, Korcok J, Gelb AW, Wilson JX (2001) Anesthetic concentrations of propofol protect against oxidative stress in primary astrocyte cultures: comparison with hypothermia. Anesthesiology 94(2):313–321View ArticleGoogle Scholar
  30. Pourpak Z, Ahmadiani A, Alebouyeh M (2004) Involvement of interleukin-1beta in systemic morphine effects on paw oedema in a mouse model of acute inflammation. Scand J Immunol 59(3):273–277. doi:https://doi.org/10.1111/j.0300-9475.2004.01396.x View ArticleGoogle Scholar
  31. Ricket A, Mateyoke G, Vallabh M, Owen C, Peppin J (2015) A pilot evaluation of a hydromorphone dose substitution policy and the effects on patient safety and pain management. J Pain Palliat Care Pharmacother 29(2):120–124. doi:https://doi.org/10.3109/15360288.2015.1035829 View ArticleGoogle Scholar
  32. Rostami F, Oryan S, Ahmadiani A, Dargahi L (2012) Morphine preconditioning protects against LPS-induced neuroinflammation and memory deficit. J Mol Neurosci 48(1):22–34. doi:https://doi.org/10.1007/s12031-012-9726-4 View ArticleGoogle Scholar
  33. Rush GF, Gorski JR, Ripple MG, Sowinski J, Bugelski P, Hewitt WR (1985) Organic hydroperoxide-induced lipid peroxidation and cell death in isolated hepatocytes. Toxicol Appl Pharmacol 78(3):473–483View ArticleGoogle Scholar
  34. Scheufler KM, Zentner J (2002) Total intravenous anesthesia for intraoperative monitoring of the motor pathways: an integral view combining clinical and experimental data. J Neurosurg 96(3):571–579. doi:https://doi.org/10.3171/jns.2002.96.3.0571 View ArticleGoogle Scholar
  35. Shelat PB, Chalimoniuk M, Wang JH, Strosznajder JB, Lee JC, Sun AY, Simonyi A, Sun GY (2008) Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem 106(1):45–55. doi:https://doi.org/10.1111/j.1471-4159.2008.05347.x View ArticleGoogle Scholar
  36. Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, Pae HO (2011) Mitogen-activated protein kinases and reactive oxygen species: How can ROS activate MAPK pathways? J Signal Transduct 2011:792639. doi:https://doi.org/10.1155/2011/792639 View ArticleGoogle Scholar
  37. Turchan-Cholewo J, Dimayuga FO, Ding Q, Keller JN, Hauser KF, Knapp PE, Bruce-Keller AJ (2008) Cell-specific actions of HIV-Tat and morphine on opioid receptor expression in glia. J Neurosci Res 86:2100–2110View ArticleGoogle Scholar
  38. Verkhrataky A, Kirchhoff F (2007) NMDA receptors in Glia. Neuroscientist 1(13):2007Google Scholar
  39. Vicente E, Degerone D, Bohn L, Scornavaca F, Pimentel A, Leite MC, Swarowsky A, Rodrigues L, Nardin P, de Almeida LM, Gottfried C, Souza DO, Netto CA, Gonçalves CA (2009) Astroglial and cognitive effects of chronic cerebral hypoperfusion in the rat. Brain Res 1251:204–212. doi:https://doi.org/10.1016/j.brainres.2008.11.032 View ArticleGoogle Scholar
  40. Watkins LR, Hutchinson MR, Rice KC, Maier SF (2009) The “toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 30(11):581–591. doi:https://doi.org/10.1016/j.tips.2009.08.002 View ArticleGoogle Scholar
  41. Wirz S, Wartenberg HC, Nadstawek J (2008) Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain. Support Care Cancer 16(9):999–1009. doi:https://doi.org/10.1007/s00520-007-0368-y View ArticleGoogle Scholar
  42. Yan LJ (2014) Positive oxidative stress in aging and aging-related disease tolerance. Redox Biol 2C:165–169. doi:https://doi.org/10.1016/j.redox.2014.01.002 View ArticleGoogle Scholar
  43. Zhang Z, Chen TY, Kirsch JR, Toung TJ, Traystman RJ, Koehler RC, Hurn PD, Bhardwaj A (2003) Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats. Anesth Analg 97(6):1776–1783View ArticleGoogle Scholar
  44. Zhang Y, Irwin MG, Wong TM (2004) Remifentanil preconditioning protects against ischemic injury in the intact rat heart. Anesthesiology 101(4):918–923View ArticleGoogle Scholar
  45. Zhang Y, Irwin MG, Lu Y, Mei B, Zuo YM, Chen ZW, Wong TM (2011) Intracerebroventricular administration of morphine confers remote cardioprotection—role of opioid receptors and calmodulin. Eur J Pharmacol 656(1–3):74–80. doi:https://doi.org/10.1016/j.ejphar.2011.01.027 View ArticleGoogle Scholar

Copyright

© The Author(s) 2016